Implementering av tobaksbehandling på platser för screening av lungcancer med låg dos CT
This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- University of Southern California (Data Collection Only)
-
Walnut Creek, California, Förenta staterna, 94598
- John Muir Health
-
-
Georgia
-
La Grange, Georgia, Förenta staterna, 30240
- WellStar Health System
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 606012
- Rush University Medical Center
-
Kankakee, Illinois, Förenta staterna, 60901
- Riverside Healthcare
-
-
Indiana
-
Crown Point, Indiana, Förenta staterna, 46307
- St. Mary Medical Center, Community Healthcare System
-
-
Iowa
-
Des Moines, Iowa, Förenta staterna, 50314
- MercyOne Des Moines Medical Center (Data Collection Only)
-
-
Maine
-
Scarborough, Maine, Förenta staterna, 04074
- Maine Medical Center Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Hospital (Data collection only)
-
Traverse City, Michigan, Förenta staterna, 49684
- Munson Healthcare
-
-
New York
-
Mineola, New York, Förenta staterna, 11501
- NYU Winthrop Hospital
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Förenta staterna, 10065
- Weill Cornell Medical Center
-
The Bronx, New York, Förenta staterna, 10467
- Montefiore Medical Center (Data Collection Only)
-
-
North Carolina
-
Morganton, North Carolina, Förenta staterna, 28655
- Carolinas Healthcare System Blue Ridge
-
-
Ohio
-
Lancaster, Ohio, Förenta staterna, 43130
- Fairfield Medical Center
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97210
- Legacy Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19140
- Temple University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Site Eligibility (as per SC self-report)
& Must be designated as an American College of Radiology (ACR) designated lung cancer screening site
- Reports at least one year of lung cancer screening experience
- Reports conducting at least 20 new initial screenings per month Site Coordinator (SC) Eligibility (as per SC self-report)
- Employed as a full-time Site Coordinator at participating lung cancer screening site Patient Eligibility (as per self-report)
- Between the ages of 50-80 years old
- Seeking baseline or annual follow-up LDCT lung cancer screening
- Have at least a 20 pack-year history of smoking
- Currently a smoker, defined as self-reported cigarette smoking (some days, every day) within the past 30 days.
- Must be reachable by telephone
- Must be English or Spanish speaking due to the study materials being available in only these languages and limited available resources for translation.
Exclusion Criteria:
Patient (as per self-report)
- NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks or, unstable/worsening angina).
- Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Motivational Interviewing( MI) (Yes vs. No)
Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session. |
two counseling sessions saliva samples from those reporting abstinence and analyze samples |
|
Experimentell: Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)
Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment. |
saliva samples from those reporting abstinence and analyze samples receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day |
|
Experimentell: NRT Lozenge (Yes vs. No)
Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment. |
saliva samples from those reporting abstinence and analyze samples 6 packs of NRT 2mg lozenge |
|
Experimentell: Message Framing (Gain vs. Loss)
Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed). |
saliva samples from those reporting abstinence and analyze samples health communication literature and quitting messages |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
number of patients who are tobacco abstinence
Tidsram: 6 months following study enrollment
|
biochemical verification of smoking abstinence will be conducted Consistent with Intent to Treat, unless self reported smoking abstinence is biochemically verified, (<3 ng/ml for mailed salivary cotinine assay) for participants who fail to return the saliva sample, the cessation outcome will be considered non-abstinent. |
6 months following study enrollment
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Jamie Ostroff, PhD, Memorial Sloan Kettering Cancer Center
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 17-500
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .